{"id":28548,"date":"2022-09-27T03:40:39","date_gmt":"2022-09-27T03:40:39","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=28548"},"modified":"2023-02-09T06:40:02","modified_gmt":"2023-02-09T06:40:02","slug":"prescient-therapeutics-investor-replay-27-september","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/","title":{"rendered":"Prescient Therapeutics Investor Replay &#8211; 27 September"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm701490a gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gmc7e355b\" class=\"wp-block-gutentor-m4 section-gmc7e355b gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmcfe8b2\" class=\"wp-block-gutentor-m4-col col-gmcfe8b2 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gmcfe8b2\" class=\"section-gmcfe8b2 gutentor-col-wrap\">\n<h2 class=\"has-text-align-center has-white-color has-text-color wp-block-heading\" style=\"font-size:33px\">Prescient Therapeutics Investor Briefing<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmb324aa3\" class=\"wp-block-gutentor-m4 section-gmb324aa3 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmd933bf\" class=\"wp-block-gutentor-m4-col col-gmd933bf gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmd933bf\" class=\"section-gmd933bf gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\" alt=\"\" class=\"wp-image-28552\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/754127366?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm396c73\" class=\"wp-block-gutentor-m4-col col-gm396c73 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm396c73\" class=\"section-gm396c73 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Senior VP of Scientific Affairs Dr Rebecca Lim provide an overview of the second component of Prescient\u2019s cell therapy enhancement platform; CellPryme-A.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, they discuss:<\/p>\n\n\n\n<ul class=\"white wp-block-list\"><li>An introduction to Prescient\u2019s newest cell therapy enhancement platform, CellPryme-A<\/li><li>The compelling data for the CellPryme-A platform to boost the effectiveness of CAR-T therapies \u2013 especially in difficult solid tumours<\/li><li>How CellPryme-A synergises with CellPryme-M and complements Prescient\u2019s next-gen CAR-T platform OmniCAR<\/li><\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 27 September 2022 at 12:00pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm5846dfd gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"speak has-text-color wp-block-heading\" style=\"color:#ffcc00\">Featured Speakers<\/h4>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\"><\/h3>\n\n\n\n<section id=\"gmc2b8a4c\" class=\"wp-block-gutentor-m4 section-gmc2b8a4c gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm954a6f\" class=\"wp-block-gutentor-m4-col col-gm954a6f gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm954a6f\" class=\"section-gm954a6f gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm6dc533\" class=\"wp-block-gutentor-m4-col col-gm6dc533 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm6dc533\" class=\"section-gm6dc533 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm27586a\" class=\"wp-block-gutentor-m4-col col-gm27586a gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm27586a\" class=\"section-gm27586a gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"306\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim.jpg\" alt=\"\" class=\"wp-image-27333\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/Rebecca-Lim-294x300.jpg 294w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"has-text-align-center speaker-heading has-white-color has-text-color wp-block-heading\">Dr Rebecca Lim<\/h3>\n\n\n\n<h4 class=\"has-text-align-center speaker-title has-white-color has-text-color wp-block-heading\">Senior Vice President of Scientific Affairs <\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr Rebecca Lim has over 10 years of experience in allogeneic cell therapies for regenerative medicine. She was previously the Scientific Director for the Cell Therapies Platform at the Hudson Institute and an Associate Professor at Monash University.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm4237ac\" class=\"wp-block-gutentor-m4-col col-gm4237ac gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm4237ac\" class=\"section-gm4237ac gutentor-col-wrap\"><\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":28552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-28548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T03:40:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-09T06:40:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Daniella Watson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniella Watson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\"},\"author\":{\"name\":\"Daniella Watson\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"headline\":\"Prescient Therapeutics Investor Replay &#8211; 27 September\",\"datePublished\":\"2022-09-27T03:40:39+00:00\",\"dateModified\":\"2023-02-09T06:40:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\"},\"wordCount\":217,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\",\"name\":\"Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"datePublished\":\"2022-09-27T03:40:39+00:00\",\"dateModified\":\"2023-02-09T06:40:02+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics Investor Replay &#8211; 27 September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\",\"name\":\"Daniella Watson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"caption\":\"Daniella Watson\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/","og_site_name":"PTX Therapeutics","article_published_time":"2022-09-27T03:40:39+00:00","article_modified_time":"2023-02-09T06:40:02+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","type":"image\/png"}],"author":"Daniella Watson","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniella Watson","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/"},"author":{"name":"Daniella Watson","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"headline":"Prescient Therapeutics Investor Replay &#8211; 27 September","datePublished":"2022-09-27T03:40:39+00:00","dateModified":"2023-02-09T06:40:02+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/"},"wordCount":217,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/","name":"Prescient Therapeutics Investor Replay - 27 September - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","datePublished":"2022-09-27T03:40:39+00:00","dateModified":"2023-02-09T06:40:02+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/09\/Frame-610.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-replay-27-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics Investor Replay &#8211; 27 September"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d","name":"Daniella Watson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","caption":"Daniella Watson"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=28548"}],"version-history":[{"count":18,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28548\/revisions"}],"predecessor-version":[{"id":29216,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/28548\/revisions\/29216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/28552"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=28548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=28548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=28548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}